Leponex

Clozapine, the active ingredient in Leponex, is a atypical antipsychotic presented as a / for oral use. It treats schizophrenia, schizoaffective disorder and treatment‑resistant schizophrenia in adult patients.

GNH USA supplies Leponex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leponex, an atypical antipsychotic, is used for disorders within the schizophrenia spectrum.

Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. Schizoaffective disorder: stabilises mood swings and psychotic features. Treatment‑resistant schizophrenia: provides symptom control when other antipsychotics have failed.

Leponex may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation - Weight gain - Constipation - Dry mouth - Dizziness - Tachycardia

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count) - Myocarditis (inflammation of the heart muscle) - Seizures - Orthostatic hypotension - Neuroleptic malignant syndrome - Severe metabolic disturbances (e.g., hyperglycaemia, dyslipidaemia)

Before initiating Leponex, clinicians should consider several safety measures.

Blood monitoring: regular complete blood counts are required to detect agranulocytosis. Cardiovascular assessment: evaluate for myocarditis and orthostatic hypotension. Seizure risk: monitor patients with a history of seizures. Metabolic monitoring: track weight, glucose and lipid levels. Pregnancy and lactation: use only if benefits outweigh potential risks. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Clozapine interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): may raise clozapine levels. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation. - Smoking cessation: nicotine withdrawal can increase clozapine concentrations.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., carbamazepine, rifampin): may reduce efficacy. - Anticholinergic agents (e.g., atropine): increase anticholinergic burden. - QT‑prolonging drugs (certain antiarrhythmics): monitor ECG for cardiac effects.